- Seda Pharma Development Services has secured a £15 million investment from BGF to expand its CRDMO capabilities.
- The funding will support facility ownership, international expansion, and increased manufacturing and development capacity.
Seda Pharma Development Services has secured a £15 million investment from BGF to support the expansion of its integrated contract research, development and manufacturing organisation (CRDMO) operations. The company, headquartered in Cheadle, Greater Manchester, provides end-to-end pharmaceutical development services from early-stage research through clinical development and registration.
The investment follows Seda’s transition from a contract research organisation (CRO) to a fully integrated CRDMO after receiving its MHRA manufacturer licence in February 2025. The company has completed more than 1,000 projects for 185 customers and continues to serve an expanding international client base.
BGF’s funding will be used to acquire the freehold of Seda’s 50,000 sq. ft manufacturing facility at Cheadle Royal Business Park, alongside supporting international expansion, strengthening business development capabilities, and further investing in manufacturing and development infrastructure. The investment is complemented by new debt facilities from Santander.
The move comes amid increasing demand for integrated outsourcing partners as pharmaceutical and biotechnology companies seek to streamline development timelines and manage regulatory requirements. Seda has previously invested £8 million in establishing its manufacturing capability at the Cheadle site.
“BGF’s investment marks a pivotal moment in Seda’s growth. It unlocks additional capital to scale our integrated CRDMO platform and enhance our technical capabilities to meet client needs.”
Dr Paul Stott, Chief Executive Officer of Seda
